I have absolutely no idea how generic marketing works... nor that MNK is not doing well marketing Seroquel because of locked in contracts.
I'm only guessing but it is a possibility that MNK has interest in IPCI and by dragging ass on Seroquel they are driving down possible takeover price... amiable or hostile... but again just brain farts.
At one time when IPCI expressed some interest in possibly becoming a distributor themselves I feared they would have to dilute and incur much expense which would push back break even point.
Now I wish they would have issued 10 million shares when stock was $3+ and gone that route.
Those are typically 6 months or one year contracts according to their CFO. He also mentioned Mallinckrodt wasn't prepared to launch on time.
If we assume that Mallinckrodt launched sales in August of 2017 - wholesale contracts should expire in March (6 months) or September 2018 (one year).
I guess we'll find out soon whether there is an increase in sales.
Having said that, I am not sure IPCI can compete price-wise with bigger players. Toronto is an expensive city to manufacture drugs for a small player like IPCI. Their volume is very low.
I hope they will figure out a way to reduce their price per pill soon.